
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Addex Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Addex Signs Option Deal with Sinntaxis for mGlu5 Use in Brain Injury Recovery
Details : Under the agreement, Sinntaxis and Addex will jointly advance the development of ADX48621 (dipraglurant), a phase II ready mGlu5 NAMr, as a potential treatment for patients with brain injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 30, 2025
Lead Product(s) : Dipraglurant
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Addex Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
